Literature DB >> 28432109

Early response to ranibizumab predictive of functional outcome after dexamethasone for unresponsive diabetic macular oedema.

Maria Vittoria Cicinelli1, Michele Cavalleri1, Lea Querques1, Alessandro Rabiolo1, Francesco Bandello1, Giuseppe Querques1.   

Abstract

PURPOSE: To analyse the effects of intravitreal dexamethasone implant in patients suffering from diabetic macular oedema (DME) on the basis of their visual and functional response to antivascular endothelial growth factor (VEGF) loading dose, in order to early shift to corticosteroids in poorly responding patients.
DESIGN: Retrospective monocentric study.
METHODS: Data of patients with diabetes shifted to 0.7 mg dexamethasone implant after three injections of ranibizumab (RNB) and followed-up to 12 months were reviewed. Main outcome was the evaluation of short-term changes after dexamethasone implant injection, stratifying patients on the basis of best-corrected visual acuity (BCVA) and central macular thickness (CMT) after RNB loading dose. Secondary outcome was to investigate clinical gain maintenance at long-term follow-up.
RESULTS: Overall, 45 eyes of 45 patients (23 males, 51.1%), mean age 69.7±9 years, were included in the analysis. After 3 injections of RNB, 30 eyes (66.7%) had a poor visual response (-4.3±10.7 letters), while 15 eyes (33.3%) disclosed good visual outcome (+13.9±9.2 letters). Patients with poor visual response were associated with limited morphological improvement (p=0.04). After 1 month from dexamethasone, only poor responders showed relevant increase in BCVA (p=0.006) and reduction in CMT (p=0.002), in comparison to good visual response patients, featuring only minor clinical effects (p=0.3). The same trend was maintained up to 12 months, after a mean of 1.9±1.1 dexamethasone administrations.
CONCLUSION: Visual and anatomical responses after RNB loading dose are significant predictors of both early term and long-term visual acuity improvement after switching to corticosteroids in patients with DME unresponsive to anti-VEGF. © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

Entities:  

Keywords:  anti-VEGF; dexamethasone; diabetic macular edema; ranibizumab

Mesh:

Substances:

Year:  2017        PMID: 28432109     DOI: 10.1136/bjophthalmol-2017-310242

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  10 in total

1.  Dexamethasone implant as an adjuvant therapy to ranibizumab loading dose in persistent diabetic macular edema.

Authors:  Akin Cakir; Burak Erden; Selim Bolukbasi; Alper Halil Bayat; Seyma Gulcenur Ozturan; Mustafa Nuri Elcioglu
Journal:  Int Ophthalmol       Date:  2018-11-23       Impact factor: 2.031

Review 2.  Profile of non-responder and late responder patients treated for diabetic macular edema: systemic and ocular factors.

Authors:  Mariacristina Parravano; Eliana Costanzo; Giuseppe Querques
Journal:  Acta Diabetol       Date:  2020-02-29       Impact factor: 4.280

Review 3.  Dexamethasone implant in the management of diabetic macular edema from clinician's perspective.

Authors:  Mojca Urbančič; Ivana Gardašević Topčić
Journal:  Clin Ophthalmol       Date:  2019-05-13

Review 4.  The Evolving Treatment of Diabetic Retinopathy.

Authors:  Sam E Mansour; David J Browning; Keye Wong; Harry W Flynn; Abdhish R Bhavsar
Journal:  Clin Ophthalmol       Date:  2020-03-04

5.  Cost-consequence analysis of extended loading dose of anti-VEGF treatment in diabetic macular edema patients.

Authors:  J M Ruiz-Moreno; F de Andrés-Nogales; I Oyagüez
Journal:  BMC Ophthalmol       Date:  2020-09-17       Impact factor: 2.209

6.  Saudi Arabia Guidelines for diabetic macular edema: A consensus of the Saudi Retina Group.

Authors:  Abdullah S AlQahtani; Mohammad A Hazzazi; Saad A Waheeb; Valmore A Semidey; Valmore A Semidey; Hussein K Elgendy; Wajeeha I Alkhars; Marwan A Abouammoh; Hassan Al-Dhibi
Journal:  Saudi Med J       Date:  2021-02       Impact factor: 1.484

7.  The Efficacy of Single-Dose Intravitreal Dexamethasone Implant for Diabetic Macular Edema Refractory to Anti-VEGF Therapy: Real-Life Results.

Authors:  Mert Simsek; Mehmet Citirik; Serdar Ozates; Kemal Tekin; Dilara Ozkoyuncu
Journal:  Beyoglu Eye J       Date:  2020-02-19

Review 8.  The role of inflammation and neurodegeneration in diabetic macular edema.

Authors:  Vincenzo Starace; Marco Battista; Maria Brambati; Michele Cavalleri; Federico Bertuzzi; Alessia Amato; Rosangela Lattanzio; Francesco Bandello; Maria Vittoria Cicinelli
Journal:  Ther Adv Ophthalmol       Date:  2021-12-05

Review 9.  Pharmacological Management of Diabetic Macular Edema in Real-Life Observational Studies.

Authors:  Laurent Kodjikian; David Bellocq; Thibaud Mathis
Journal:  Biomed Res Int       Date:  2018-08-28       Impact factor: 3.411

10.  Effect of intravitreal dexamethasone solution on the reduction of macular thickness in pseudophakic diabetic patients in a public hospital in Brazil: a randomized clinical trial.

Authors:  Andre Luis A Fonseca; Heitor Panetta; Mauricio A Nascimento; Rodrigo Pessoa C Lira; Carlos Eduardo L Arieta
Journal:  Clin Ophthalmol       Date:  2019-08-09
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.